Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)
Completed
Vanda Pharmaceuticals
Phase 4
2014-05-01
Hetlioz™ (tasimelteon) is used in the treatment of Non-24-Hour-Sleep-Wake Disorder (Non-24).
Non-24 is very common in people who are totally blind because light can not reset their body
clock. This causes the internal sleep-wake cycle to be out of sync with the 24-hour
day-night. Non-24 is a serious, chronic circadian rhythm disorder in the blind that causes
nighttime sleep problems and a wide range of daytime difficulties, including an overwhelming
urge to nap.
Tasimelteon will be given in two ways; orally (by mouth) as a 20 mg capsule and intravenously
(I.V.) by infusion through a catheter (not an injection) into a vein. The oral administration
is approved by the FDA. The I.V. administration is considered investigational as it has not
been approved by the FDA. This will be the first time tasimelteon will be given to humans by
intravenous (I.V.) injection.
The purposes of this research study are to:
- assess how quickly a single 20 mg oral dose of tasimelteon is absorbed into the body;
- evaluate the single-dose pharmacokinetics of tasimelteon after a single 20 mg oral dose
and after a single 2 mg I.V. dose;
- evaluate the single-dose pharmacokinetics of tasimelteon metabolites after a single 20
mg oral dose and after a single 2 mg I.V. dose;
- evaluate the safety and tolerability of a single 20 mg oral dose of tasimelteon; and
- evaluate the safety and tolerability of a single 2 mg I.V. dose of tasimelteon.
Pharmacokinetics (PK) is the study of how a drug is absorbed, distributed, metabolized, and
eventually eliminated by the body. Pharmacokinetics is what the body does to the drug. Blood
samples will be taken throughout the study for PK analysis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
